MedTrace Logo

Immediate Therapeutic Effects of Diquafosol and Rebamipide in Dry Eye Disease

NCT07297316 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-12-22

No results posted yet for this study

Summary

This study compares the immediate therapeutic and mucin-secreting effects 30 minutes after instillation of 3% diquafosol and 2% rebamipide in dry eye disease.

Conditions

  • Dry Eye Disease (DED)

Interventions

DRUG

3% diquafosol (right eye) and 2% rebamipide (left eye)

3% diquafosol was instilled in the right eye and 2% rebamipide in the left eye.

DRUG

2% rebamipide (right eye) and 3% diquafosol (left eye)

2% rebamipide was instilled in the right eye and 3% diquafosol in the left eye.

Sponsors & Collaborators

  • Kukje Pharma

    collaborator OTHER

  • Korea University Anam Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-03
Primary Completion
2024-08-30
Completion
2024-08-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07297316 on ClinicalTrials.gov